Huovilainen A, Kinnunen L, Ferguson M, Hovi T
Department of Virology, National Public Health Institute, Helsinki, Finland.
J Gen Virol. 1988 Aug;69 ( Pt 8):1941-8. doi: 10.1099/0022-1317-69-8-1941.
Antigenic properties of 128 clinical type 3 poliovirus isolates of the 1984 to 1985 Finland outbreak from 95 persons and 45 strains from sewage water specimens were evaluated using five neutralizing monoclonal antibodies (MAbs) directed against an antigenic site (designated site 1) on VP1 at amino acids 89 to 100. All five MAbs neutralized the type 3 poliovirus strains used in the vaccines, P3/Saukett and P3/Sabin, but none of them neutralized the prototype strain of the outbreak (P3/Finland/23127/84). Forty-six percent of the clinical isolates resembled the prototype strain (class A) while the rest of the isolates were neutralized by one or more of the MAbs (classes B to D). Although an antigenic drift from A to one of the other classes was observed in sequential specimens from several individuals, no clear-cut overall change in the class distribution was found within the 3 months time span of the outbreak. Homogeneous virus populations were isolated from the sewage specimens using a microtitre endpoint dilution method. The last positive sewage specimens which were obtained in January to February 1985 still had a majority of the class A strain. Some of the clinical isolates were also tested using MAbs directed against distinct antigenic sites. These studies showed that strains that gave the same pattern of reactivity with site 1 MAbs could be differentiated using antibodies directed against other sites. Fifteen strains belonging to different antigenic subclasses were subjected to partial RNA sequencing of the genome region coding for antigenic site 1. The antigenic variation was usually, but not always associated with corresponding amino acid substitutions in antigenic site 1. These results indicate that the antigenic sites of type 3 poliovirus vary extensively within a given outbreak and even during replication in a given host. This variation may have both pathogenetic and epidemiological significance.
利用5种针对VP1上89至100位氨基酸处抗原位点（命名为位点1）的中和单克隆抗体（MAb），对1984年至1985年芬兰疫情中从95人身上分离出的128株临床3型脊髓灰质炎病毒以及污水样本中的45株病毒的抗原特性进行了评估。所有5种MAb均可中和疫苗中使用的3型脊髓灰质炎病毒株P3/Saukett和P3/Sabin，但均不能中和疫情的原型株（P3/Finland/23127/84）。46%的临床分离株与原型株相似（A类），其余分离株可被一种或多种MAb中和（B至D类）。尽管在几名个体的连续样本中观察到从A类到其他类之一的抗原漂移，但在疫情的3个月时间跨度内未发现类分布有明显的总体变化。使用微量滴定终点稀释法从污水样本中分离出了同源病毒群体。1985年1月至2月获得的最后一批阳性污水样本中，仍以A类菌株为主。部分临床分离株也使用针对不同抗原位点的MAb进行了检测。这些研究表明，对位点1 MAb产生相同反应模式的菌株可使用针对其他位点的抗体进行区分。对属于不同抗原亚类的15株菌株进行了编码抗原位点1的基因组区域的部分RNA测序。抗原变异通常但并非总是与抗原位点1中的相应氨基酸替换相关。这些结果表明，3型脊髓灰质炎病毒的抗原位点在给定疫情期间甚至在给定宿主的复制过程中都有广泛变化。这种变异可能具有致病和流行病学意义。
